Drug Profile
LCB10 0200
Alternative Names: GT-1; LCB10-0200Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator LegoChem Biosciences
- Developer Geom Therapeutics; LegoChem Biosciences
- Class Antibacterials; Cephalosporins; Small molecules
- Mechanism of Action Cell wall inhibitors; Penicillin-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in Australia (IV, Infusion)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (SC, Injection)
- 22 Jun 2020 Preclinical antimicrobial data in Gram negative infections presented at the ASM Microbe 2020 (ASMM-2020)